Randomized trial · people

Teriparatide then denosumab: spine density up 18.3% over 4 years

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, the order mattered: going from teriparatide to denosumab kept bone density rising, while going from denosumab to teriparatide gave smaller gains at the hip and a loss at the wrist.

Kind
Randomized trial
Studied in
People
Number studied
77
Published
2015
Journal
Lancet

What they tested

The team set out to test how bone density changes when women with osteoporosis after menopause switch between teriparatide and denosumab.

How the study was done

A randomized controlled extension of the DATA trial in 77 women with osteoporosis after menopause. After 24 months on teriparatide, denosumab or both, they switched treatments for 24 more months: teriparatide to denosumab, denosumab to teriparatide, or the combination to denosumab alone.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Over 4 years, spine bone mineral density (BMD) rose 18.3% in the teriparatide to denosumab group, 14.0% in the denosumab to teriparatide group and 16.0% in the combination to denosumab group. These spine differences were not statistically significant. Total hip BMD rose 6.6% after teriparatide to denosumab, compared with 2.8% after denosumab to teriparatide, and 8.6% in the combination to denosumab group. Wrist (radius) BMD was unchanged at 0.0% after teriparatide to denosumab, fell 1.8% after denosumab to teriparatide, and rose 2.8% in the combination to denosumab group.

What it doesn’t show

The groups were small, with 23 to 27 women each, and the study measured bone density and bone turnover markers, not fractures. It was funded in part by Amgen and Eli Lilly.

The paper

Leder et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015.

The compound

More studies on Teriparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo